GRPR and cancer: In vitro and in vivo studies demonstrated that the carborane-functionalized GRPR agonist was highly selective and effective in targeting cancer cells that overexpress GRPR, leading to increased uptake of boron-containing compounds and improved therapeutic efficacy in mouse models of cancer 83.